More recently, a selective small molecule inhibitor of EZH2 “Tazemetostat (EPZ-6438)” has been clinically tested in patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma, or histiocytic disorders with EZH2 and other gene mutations. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.